Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Geoffrey Gibney

Hematology | Oncology
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
Offers Telehealth
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Geoffrey Gibney is a Hematologist and an Oncologist in Washington, Washington, D.c.. Dr. Gibney is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Sinus Cancer, and Teratocarcinosarcoma.

His clinical research consists of co-authoring 86 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Specialties
Hematology
Oncology
Licenses
Internal Medicine in DC
Hospital Affiliations
Medstar Georgetown University Hospital
Medstar Washington Hospital Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

MGMC LLC
3800 Reservoir Rd Nw, Washington, DC 20007

Additional Areas of Focus

Dr. Gibney has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drug: Adavosertib
Study Phase: Phase 2
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Drug
Study Drugs: Spartalizumab, LAG525, Capmatinib, Canakinumab, Ribociclib
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Biological
Study Drug: ITIL-168
Study Phase: Phase 2
A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy
A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Enrollment Status: Terminated
Publish Date: April 04, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Enrollment Status: Terminated
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

86 Total Publications

Cellular Therapy for Advanced Melanoma.
Cellular Therapy for Advanced Melanoma.
Journal: The Surgical clinics of North America
Published: May 24, 2025
Similar Doctors
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Julie E. Bauman
Hematology Oncology | Hematology | Oncology
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Julie E. Bauman
Hematology Oncology | Hematology | Oncology

Medical Faculty Associates, Inc

2150 Pennsylvania Ave Nw, 
Washington, DC 
 (1.6 miles away)
202-741-2600
Languages Spoken:
English
See accepted insurances

Julie Bauman is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Bauman is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Glioma, Tongue Cancer, Nasopharyngeal Carcinoma, and Tissue Biopsy.

Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Ranee Mehra
Oncology | Hematology
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Ranee Mehra
Oncology | Hematology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (35.5 miles away)
410-328-1230
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ranee Mehra is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mehra is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Tongue Cancer, and Glossectomy. Dr. Mehra is currently accepting new patients.

Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. David Sidransky
Oncology | Otolaryngology
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. David Sidransky
Oncology | Otolaryngology
720 Rutland Ave, 
Baltimore, MD 
 (37.2 miles away)
410-502-5153
Languages Spoken:
English
See accepted insurances

David Sidransky is an Oncologist and an Otolaryngologist in Baltimore, Maryland. Dr. Sidransky is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adenoid Cystic Carcinoma, Salivary Gland Tumors, and Polymorphous Low Grade Adenocarcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gibney's expertise for a condition
ConditionClose
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile